LANCL1

Across TCGA pan-cancer cohorts, LANCL1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LANCL1 data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher LANCL1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LANCL1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LUAD, CCRCC, and LSCC are the cancer types where LANCL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.358	0.863	.002	19	view →
CCRCC	OS	Tertile	III,IV	0.985	0.104	.024	9	view →
LSCC	OS	Quartile	II,III,IV	0.542	0.943	.011	6	view →
PDAC	OS	Median	IV	0.937	0.395	.026	6	view →
GBM	DFS	Quartile	All	0.826	0.651	.015	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LANCL1–LUAD (DFS)

Open the LUAD breakdown →